Healthcare apparel was not supposed to be the most exciting trade on Wall Street in early August. Then FIGS posted Q2 results on the evening of August 6, 2026, and the stock jumped about 27% in a single session, closing Friday at $14.26. Over the full week it gained about 33%. That kind of move demands a second look, because the headline numbers and the underlying ones tell two very different stories.
Market Temperature
The broader consumer discretionary space has been navigating a tricky stretch: sticky goods inflation, a softening jobs picture, and tariff policy that has shifted after the Supreme Court’s February 2026 decision on IEEPA duties. Against that backdrop, any company showing 25%-plus revenue growth with margin expansion gets attention fast. FIGS got it in full.
The IEEPA tariff landscape shifted dramatically after the Supreme Court’s February 2026 ruling found certain IEEPA tariffs unlawful, triggering a refund process through U.S. Customs and Border Protection. Companies that moved quickly to claim recoveries booked one-time benefits into reported results. FIGS is one of them, and that fact sits at the center of every valuation conversation happening right now.
What FIGS Actually Is
Santa Monica-based FIGS sells premium scrubwear and adjacent healthcare apparel direct-to-consumer, almost entirely through its website and mobile app. Unlike most apparel companies, it does not sell product driven by fad or seasonal inventory risk. Scrubs and lab coats are replenishment-driven uniforms that healthcare professionals need year round. That structural distinction matters enormously when thinking about demand durability.
The company targets a U.S. healthcare workforce measured in the tens of millions. With less than 1% global market share, FIGS has emphasized its runway for continued growth through increased brand awareness, share of wallet expansion, international penetration, institutional sales, and retail expansion. The category is not niche. The current penetration rate just makes it look that way.
Data-Driven Deep Dive
FIGS reported stronger-than-expected Q2 2026 results, with adjusted earnings of $0.15 per share and revenue of $196.6 million, topping Wall Street estimates of $0.07 and $186.1 million, respectively. Net revenues grew 29% year over year, marking the company’s third straight quarter with 25%-plus growth.
Customer metrics were equally strong. Active customers reached 3.1 million as of June 30, 2026, a 13.2% year-over-year increase. Net revenues per active customer were $229, up 10.1%. Average order value hit a company record of $127, rising 8.5% on higher average unit retail and favorable product mix. That last figure matters: it tells you customers are not just returning, they are trading up.
The revenue mix is also broadening. Scrubwear revenue grew 26.5% to $161.2 million while non-scrubwear revenue jumped 40.3% to $35.4 million. FORMx fabric penetration nearly doubled year over year, and FIGS plans to spotlight its FIBREx line more meaningfully in the second half of 2026. That product layering is the wallet-share story: FIGS is building a head-to-toe healthcare wardrobe, not just selling scrub sets.
On capital allocation, share repurchases during the quarter totaled approximately $24 million at a weighted average price of $11.94 per share. The company has now repurchased approximately $81 million cumulatively since initiating the program. The board authorized an additional $100 million increase, bringing total share repurchase capacity to $119 million. First-half free cash flow improved to $38.6 million, compared to negative $5.6 million in the same period a year earlier.
Strategic Insight: Why the Valuation Question Is Harder Than It Looks
Here is where the analysis gets harder. FIGS recognized a $20.5 million IEEPA tariff recovery in Q2, including a $15.4 million reduction to cost of goods sold and a $5.1 million inventory adjustment. The refund supports 2026 margins and cash flow, but it is a nonrecurring benefit. Investors need to separate it from underlying performance before anchoring to any forward margin estimate.
That $20.5 million flows directly through gross margin. Gross margin expanded to 75.2%, up 820 basis points year over year, with most of that improvement coming from IEEPA tariff refunds along with favorable pricing and efficiency gains. Strip the refund out, and the underlying gross margin improvement looks considerably narrower. This does not make the quarter a miss. It does change the forward margin trajectory investors should anchor to heading into Q3 and Q4.
The guidance raise deserves credit nonetheless. FIGS raised its full-year 2026 revenue growth outlook to approximately 20%, up from a prior range of 14% to 16%. Management also lifted its full-year operating margin outlook to about 10.8% from 7.8% to 8.0%, and its adjusted EBITDA margin outlook to 14.8% to 15.0% from 13% to 13.2%. Those numbers moved up even while a simultaneous supply chain disruption was actively unfolding, which is the part of the story that commands the most scrutiny.
Risks
On June 23, 2026, CBP issued a Withhold Release Order against two Jordanian garment manufacturers, citing forced labor concerns. According to the company’s Q2 10-Q, one of FIGS’s Jordan-based manufacturing partners was covered by the order, and that supplier produced about one-third of Q2 finished goods. The WRO is expected to reduce second-half revenue, gross margin, and inventory levels.
The company is shifting production to other suppliers and expediting output through existing partners. FIGS expects to use air freight for certain products, which will partially offset other margin benefits. Third-quarter inventory is expected to remain down double digits year over year because of supplier transitions, though management says it can still support its raised revenue targets.
Three risks stack here simultaneously. First, new U.S. import tariffs on some sourcing routes are increasing product costs and pressuring gross margin despite mitigation efforts. Second, non-scrubwear is growing quickly, but it carries lower margins than scrubwear, meaning the product mix shift driving revenue diversity is simultaneously creating a margin headwind. Third, the Q4 revenue growth guide decelerates to approximately 10%, roughly half the pace of Q2 and Q3. That deceleration is baked in, but it could cool investor enthusiasm if it arrives with any further supply friction.
On valuation, the stock now trades at a P/E that is well above peers. At about 47x forward earnings, FIGS sits roughly double the broad apparel peer averages many investors use as a benchmark. Analyst price targets also moved up sharply following Q2. At Friday’s close of $14.26, the stock is already near the lower end of that revised target range, which means the re-rating from the earnings catalyst may already be priced in.
Big Picture
The structural case for FIGS is not manufactured. Healthcare and social assistance is projected to be the fastest growing U.S. industry sector from 2024 to 2034, driven by the needs of an aging population and rising demand for care. A replenishment-driven uniform business aimed directly at that workforce has a defensible long-term position that most apparel companies cannot replicate.
The international dimension adds another leg to the runway. FIGS generated $28.3 million in international net revenues in Q1 2026, up 49.9% year over year, and the company has said it now operates in 85 international markets. The pace of that geographic build-out reflects execution, not just aspiration. Management declined to give 2027 guidance but pointed to low market penetration and expanding international opportunities as reasons to believe the growth profile extends well beyond this year.
The Community Hub retail expansion also deserves attention. Roughly 40% of Community Hub visitors are new to the brand, suggesting physical locations are acting as customer acquisition tools rather than simply converting existing fans. For a company that built itself as digital-first, that acquisition efficiency from physical retail is a meaningful data point about how FIGS can grow its 3.1 million active customer base without proportionate increases in marketing spend.
Final Thought
FIGS earned its Q2 rally. Three consecutive quarters of 25%-plus growth, a record average order value, a customer base spending more per visit, and a guidance raise delivered through an active supply chain disruption: that combination deserved a re-rating. The stock got one, decisively.
The question now is whether the re-rating overshot. The demand signal is clearly strong enough to absorb the Jordan disruption, or management would not have lifted the full-year outlook while rerouting supply. But a $20.5 million tariff refund that will not recur, a Jordan supplier that produced a third of Q2 finished goods and is now disrupted, ongoing tariff headwinds with no refund mechanism, and a P/E near 47x: those are the variables that determine whether $14 is a fair starting point or the ceiling of the trade.
FIGS could be worth significantly more in 2027 if the underlying business runs at the pace the past three quarters suggest. It could also be fully valued right here if the H2 margin story disappoints once the tailwinds are gone. The second half of 2026 answers the question. This one is worth watching closely before adding conviction.
Subject Line: FIGS Jumped 27%. Now What?
Preheader: A one-time $20.5M tariff refund and a Jordan WRO are the two numbers the market hasn’t finished processing.
Meta Description: FIGS posted a blowout Q2, raised guidance, and surged 27%. But a nonrecurring tariff refund and a Jordan supply disruption raise real questions about the H2 margin story and whether the stock is already fully valued.
Disclaimer: This editorial is for informational purposes only and does not constitute investment advice. The information presented reflects publicly available data as of August 10, 2026. Past performance is not indicative of future results. Readers should conduct their own research and consult a qualified financial advisor before making any investment decisions.
